10Y UST5.24%-0.95%30Y MTG7.28%+3.56%SOFR3.88%+0.26%VNQ$89.50+0.37%XLRE$40.81+0.32%FED FUNDS3.88%
Real Estate Trail
Institutional Press Wire
PR Newswire · Tampa

TuHURA Biosciences Receives Key U.S. Patent for its Groundbreaking Delta Opioid Receptor (DOR) Antibody Drug Conjugate (ADC) Technology

Via PR Newswire · October 5, 2026
Compiled by Real Estate Trail Editorial · October 5, 2026

Why this matters

Commercial real estate continues to digest a multi-year reset in cost of capital. Transaction velocity is below the 2019-2021 trend but improving, cap rates have stabilized across most stabilized property types, and the bid-ask gap has narrowed materially in the past two quarters. Sponsors with permanent capital and operating platforms have an advantage in the current execution environment. In Tampa, capital is selective and basis-driven, with allocators favoring sponsors who can demonstrate execution rather than financial engineering. The next twelve months will continue to reward underwriting discipline and operational sophistication over balance-sheet aggression.

Editorial analysis · Real Estate Trail Editorial

On the RET wire

Computed from Real Estate Trail’s own tracked coverage

Excerpt from PR Newswire:
Patent discloses uses beyond ADCs, including autologous or allogeneic adoptive cellular immunotherapies like CAR-T, Tregs or TIL cell therapies TAMPA, Fla., Oct. 5, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDA…
Read the full article at PR Newswire →

External link. Real Estate Trail does not republish source content.

Related coverage — Tampa

More from the wire